Evonik Invests $100 million to Upgrade its Lafayette Site

Evonik is making a significant investment to strengthen manufacturing capabilities at its Lafayette (Tippecanoe), Indiana facility. Over the next five years, the company will invest US$100 million to modernize key equipment – including 100 m³ reactors and other critical systems – enhancing reliability, enabling greater automation, and improving ergonomics and efficiency. This investment is supported by local government and positions Evonik to meet the rapidly growing demand for U.S.-based drug substance CDMO services.

“Strengthening our U.S. drug substance business is a strategic necessity. With demand surging, Tippecanoe plays a pivotal role in creating a more resilient and globally balanced asset footprint,” said Guido Skudlarek, head of the Health Care business line at Evonik.

Read More